ACA
Avoro Capital Advisors Portfolio holdings
AUM
$5.71B
This Quarter Return
+34.31%
1 Year Return
+11.37%
3 Year Return
+255.37%
5 Year Return
+558.9%
10 Year Return
+18,722.72%
AUM
$8.57B
AUM Growth
+$8.57B
(+18%)
Cap. Flow
+$830M
Cap. Flow
% of AUM
9.68%
Top 10 Holdings %
Top 10 Hldgs %
58.85%
Holding
53
New
11
Increased
15
Reduced
3
Closed
7
Top Buys
| 1 |
Viking Therapeutics
VKTX
|
$294M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$229M |
| 3 |
Vera Therapeutics
VERA
|
$227M |
| 4 |
Arrowhead Research
ARWR
|
$212M |
| 5 |
MacroGenics
MGNX
|
$90.5M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$287M |
| 2 |
CBAY
Cymabay Therapeutics
CBAY
|
$262M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$121M |
| 4 |
Structure Therapeutics
GPCR
|
$95.1M |
| 5 |
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
|
$39.6M |
Sector Composition
| 1 | Healthcare | 94.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
United Therapeutics
UTHR
$13.8B
| $657M | 7.66% | 2,858,888 | – | – |
|
2
Apellis Pharmaceuticals
APLS
$3.48B
| $653M | 7.62% | 11,111,111 | – | – |
|
3
Ascendis Pharma
ASND
$11.8B
| $600M | 6.99% | 3,966,666 +211,111 | +6% | +$31.9M |
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $562M | 6.56% | 4,344,444 | – | – |
|
5
Madrigal Pharmaceuticals
MDGL
$9.76B
| $519M | 6.06% | 1,944,444 +55,556 | +3% | +$14.8M |
|
6
argenx
ARGX
$43.6B
| $488M | 5.69% | 1,238,467 +3,900 | +0.3% | +$1.54M |
|
7
Krystal Biotech
KRYS
$4.27B
| $455M | 5.3% | 2,555,555 -10,000 | -0.4% | -$1.78M |
|
8
SPDR S&P Biotech ETF
XBI
$5.07B
| $408M | 4.76% | 4,300,000 -144,444 | -3% | -$13.7M |
|
9
BioMarin Pharmaceuticals
BMRN
$11.2B
| $381M | 4.45% | 4,365,000 +65,000 | +2% | +$5.68M |
|
10
Amicus Therapeutics
FOLD
$2.34B
| $323M | 3.76% | 27,400,000 | – | – |
|
|
CERE
11
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $319M | 3.73% | 7,555,555 | – | – |
|
|
12
Viking Therapeutics
VKTX
$3.04B
| $294M | 3.43% | +3,590,000 | New | +$294M |
|
|
13
Arrowhead Research
ARWR
$3.05B
| $245M | 2.85% | 8,555,555 +7,425,555 | +657% | +$212M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $244M | 2.85% | 5,666,666 | – | – |
|
|
ALPN
15
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $229M | 2.67% | +5,775,000 | New | +$229M |
|
|
16
Vera Therapeutics
VERA
$1.38B
| $227M | 2.65% | +5,265,000 | New | +$227M |
|
17
Iovance Biotherapeutics
IOVA
$807M
| $173M | 2.02% | 11,700,000 +5,000,000 | +75% | +$74.1M |
|
|
ITCI
18
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $171M | 2% | 2,475,000 +219,445 | +10% | +$15.2M |
|
19
Kymera Therapeutics
KYMR
$2.95B
| $156M | 1.82% | 3,888,888 +113,888 | +3% | +$4.58M |
|
20
Avidity Biosciences
RNA
$5.99B
| $149M | 1.73% | 5,825,000 +3,315,000 | +132% | +$84.6M |
|
21
MoonLake Immunotherapeutics
MLTX
$3.54B
| $130M | 1.51% | 2,580,000 | – | – |
|
22
Syndax Pharmaceuticals
SNDX
$1.41B
| $100M | 1.17% | 4,222,222 | – | – |
|
|
23
MacroGenics
MGNX
$112M
| $90.5M | 1.06% | +6,150,000 | New | +$90.5M |
|
24
Kura Oncology
KURA
$686M
| $82.1M | 0.96% | 3,850,000 +870,000 | +29% | +$18.6M |
|
|
AUTL
25
Autolus Therapeutics
AUTL
$399M
| $78.8M | 0.92% | +12,345,678 | New | +$78.8M |
|